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ABSTRACT
Objective To investigate the cost effectiveness of
ticagrelor versus clopidogrel in patients with acute
coronary syndromes (ACS) in the Platelet Inhibition and
Patient Outcomes (PLATO) study who were scheduled for
non-invasive management.
Methods A previously developed cost effectiveness
model was used to estimate long-term costs and
outcomes for patients scheduled for non-invasive
management. Healthcare costs, event rates and health-
related quality of life under treatment with either
ticagrelor or clopidogrel over 12 months were estimated
from the PLATO study. Long-term costs and health
outcomes were estimated based on data from PLATO
and published literature sources. To investigate the
importance of different healthcare cost structures and life
expectancy for the results, the analysis was carried out
from the perspectives of the Swedish, UK, German and
Brazilian public healthcare systems.
Results Ticagrelor was associated with lifetime quality-
adjusted life-year (QALY) gains of 0.17 in Sweden, 0.16
in the UK, 0.17 in Germany and 0.13 in Brazil compared
with generic clopidogrel, with increased healthcare costs
of €467, €551, €739 and €574, respectively. The cost
per QALY gained with ticagrelor was €2747, €3395,
€4419 and €4471 from a Swedish, UK, German and
Brazilian public healthcare system perspective,
respectively. Probabilistic sensitivity analyses indicated
that the cost per QALY gained with ticagrelor was below
conventional threshold values of cost effectiveness with
a high probability.
Conclusions Treatment of patients with ACS scheduled
for 12 months’ non-invasive management with ticagrelor
is associated with a cost per QALY gained below
conventional threshold values of cost effectiveness
compared with generic clopidogrel.
Trial registration number NCT000391872.
INTRODUCTION
Worldwide, 40–60% of patients with non-ST-
elevation acute coronary syndromes (ACS) are med-
ically managed without revascularisation. These
patients have an increased risk of mortality, and
receive antiplatelet therapy after discharge less fre-
quently than patients who undergo revascularisa-
tion.1 2 Current guidelines recommend an early
invasive approach in high-risk patients with
non-ST-elevation ACS,3 4 but whether this consist-
ently reduces mortality remains unclear.
Dual antiplatelet therapy with aspirin and a
P2Y12 inhibitor is recommended for 12 months in
patients with ACS not undergoing invasive
therapy.3 In the Platelet Inhibition and Patient
Outcomes (PLATO) trial in 18 624 patients with
ACS,5 a prespeciﬁed analysis of 5216 patients who
were planned at randomisation for non-invasive
management demonstrated that, compared with
clopidogrel, ticagrelor signiﬁcantly reduced the rate
of ischaemic events including the primary compos-
ite end point of myocardial infarction, stroke or
death from vascular causes.6 Cardiovascular and
all-cause mortality were also signiﬁcantly reduced
with ticagrelor.6 The incidence of total major
bleeding and non-coronary artery bypass grafting-
related major bleeding was numerically higher with
ticagrelor than with clopidogrel,6 but these failed
to reach statistical signiﬁcance. These ﬁndings were
consistent with the overall PLATO results.
In addition to clinical beneﬁt, healthcare decision
makers need to consider costs in order to prioritise
treatments. The cost effectiveness of ticagrelor over
generic clopidogrel in the overall PLATO popula-
tion has been shown from an European healthcare
perspective.7 The economic implications of using
ticagrelor in the subgroup of patients with ACS
intended for non-invasive management were not
analysed in the previous study and the aim of this
work was therefore to investigate the cost effective-
ness of ticagrelor with generic clopidogrel in this
subgroup. In order to investigate the impact of tica-
grelor in a range of countries with different health-
care systems and life expectancy, the cost
effectiveness analysis was conducted from the per-
spectives of four different public systems: Sweden,
the UK, Germany and Brazil.
METHODS
Overview
The PLATO trial (NCT00391872) enrolled 18 624
patients from 43 countries between October 2006
and July 2008; full details of the study design,
inclusion criteria and results have already been pub-
lished.5 6 Brieﬂy, patients with ST-segment eleva-
tion ACS scheduled for primary percutaneous
coronary intervention or non-ST segment elevation
ACS, with onset of symptoms during the previous
24 h, were enrolled.
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At randomisation, physicians initially allocated patients to
intended invasive or conservative non-invasive management via
an interactive voice randomisation system. These initial deci-
sions were non-binding but were required to create statistically
valid prospectively identiﬁed therapy groups; after randomisa-
tion, physicians were free to manage patients according to their
clinical judgement. Patients were randomised to receive either
ticagrelor 90 mg twice daily after a loading dose of 180 mg, or
clopidogrel 300 mg loading dose (if required) with an additional
300 mg load allowed for patients undergoing percutaneous cor-
onary intervention (PCI) , followed by 75 mg daily. All patients
also received aspirin if tolerated; randomised treatment contin-
ued for 6–12 months. At the time of randomisation, 5216
(28%) patients were allocated initially to non-invasive manage-
ment.6 Of these, 2601 and 2615 were randomised to ticagrelor
and clopidogrel, respectively. To handle administrative censoring
when analysing resource use, only patients eligible for
12 months’ follow-up were included in the 12-month cost ana-
lysis (1499 ticagrelor, 1516 clopidogrel).
Lifetime costs and outcomes were estimated using the same
two-part decision-analytical model used in the previous PLATO
cost effectiveness analysis.7 Individual patient data from PLATO
were used to determine rates of cardiovascular events, resource
use and health-related quality of life for 12 months of therapy.
Beyond the 1st year, a Markov structure was used for long-term
extrapolation in order to estimate quality-adjusted survival con-
ditional on whether a non-fatal stroke or a non-fatal myocardial
infarction (MI) had occurred (ﬁgure 1). Full details of the
model and its application have been published previously.7 To
investigate the impact of different healthcare systems and life
expectancy, the cost-effectiveness analysis was conducted from
the perspectives of four different public systems: those of
Sweden, the UK, Germany and Brazil. All costs were expressed
in Euros (€) using 2010 prices and the average exchange rates
for that year (€1=Kr9.54, €1=£0.86 and €1=R$2.33).8 9 Costs
and health outcomes were discounted according to guidelines:
3%, 3.5% and 5% per annum in the Swedish, German, UK and
Brazilian analyses, respectively.10 11 Results are presented as
incremental cost effectiveness ratios showing the additional cost
per unit of health outcome of treating patients with ticagrelor
compared with clopidogrel.
Data
The event risks for 12 months treatment with ticagrelor and clo-
pidogrel were estimated for different clinical pathways using a
parametric survival model and are reported in table 1 for the
following clinical pathways: non-fatal MI occurring before a
potential non-fatal stroke with no subsequent fatal event; a non-
fatal stroke occurring before any potential non-fatal MI with no
subsequent fatal event; death occurring at any point in the study
follow-up; no further event. Following the approach in Nikolic
et al,7 and in line with the clinical ﬁndings in PLATO,6 the risks
for clopidogrel-treated patients were estimated using the sample
of non-invasive patients whereas the overall treatment effects
observed in the full PLATO sample were applied to derive the
risks for ticagrelor-treated patients. In an alternative scenario
the treatment effect observed in the non-invasive cohort was
applied.
Cost estimates per clinical pathway were based on resource
use data collected in PLATO, as previously described.7 Brazilian,
UK, German and Swedish unit costs were derived from national
public databases for each country,12–15 and were multiplied with
observed resource use to arrive at a total healthcare cost per
patient in the study. Expert opinion was used for those German
unit costs that were not feasible to derive from another source.
Resource use, unit cost data and within-trial cost estimates are
supplied in an online appendix to this article (see online
supplementary table S1). The estimated costs per clinical
pathway derived from the cost analysis and applied in the
model are provided in table 1.
Daily drug costs for ticagrelor and generic clopidogrel were
applied during the 12 months of therapy as long as patients
were alive. This is a conservative assumption as it disfavours the
ticagrelor strategy and follows Nikolic et al.7 The drug cost for
each country is reported in table 1.
Quality-adjusted life-year (QALY) estimates for the clinical
pathways were based on EuroQol 5 dimensions (EQ-5D)16 data
collected prospectively in PLATO. The widely used UK tariff
was applied to derive QALY-weights from the answers of the
EQ-5D instrument.7 A 12-month QALY estimate was calculated
for every patient with planned 12-month follow-up: for all
patients still alive after all three measurements (index, 6 months
and 12 months), the area under the curve was estimated
Figure 1 Decision tree and Markov
model.7 Markov model transitions
shown in this ﬁgure: (1) risk of
non-fatal myocardial infarction (MI) for
patients with no MI or stroke in the
PLATO study. (2) Risk of non-fatal
stroke for patients with no MI or
stroke in the PLATO study.
(3) Mortality risk for patients with no
MI or stroke in the PLATO study.
(4) Mortality risk at the 1st year after a
non-fatal MI. (5) Mortality risk at the
1st year after a non-fatal stroke.
(6) Mortality risk at second and
subsequent years after a non-fatal MI.
(7) Mortality risk at second and
subsequent years after a non-fatal
stroke. This model structure was
developed by Nikolic et al,7 and is
used with the permission of the
European Heart Journal. ACS, acute
coronary syndrome; PLATO, Platelet
Inhibition and Patient Outcomes.
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assuming a linear relationship between all time points. The last
available estimates were carried forward until the date of death
for patients who died. The estimated mean per patient
12-month QALY estimates per clinical pathway are reported in
table 1.
Parameters used for long-term extrapolation (beyond
12 months) are listed in table 2. Annual risks of non-fatal MI
and non-fatal stroke (transitions 1 and 2 in ﬁgure 1) were esti-
mated by extrapolating observed hazard functions from the clo-
pidogrel arm in PLATO beyond 1 year’s follow-up. Long-term
survival was based on country-speciﬁc life tables with applica-
tion of HRs to account for increase in risk due to further events
(transitions 3–7 in ﬁgure 1), while costs and QALY weights for
each health state in the Markov model were based on PLATO
data and published literature (see Nikolic et al7).
Analysis
The base-case analysis was based on the full population of
patients with ACS scheduled non-invasive management. An
alternative scenario included only patients with NSTE-ACS who
did not undergo any revascularisation procedure (PCI or coron-
ary artery bypass grafting (CABG)) with or without angiography
during the ﬁrst 10 days.17
Uncertainty in the estimated incremental cost effectiveness
ratios due to sampling uncertainty in the estimated input param-
eter values was evaluated by employing probabilistic sensitivity
analysis in which simulation was used to propagate uncertainty
in individual model inputs through the model in order to assess
the uncertainty in the outcome of interest, incremental cost
effectiveness. Furthermore, scenarios were also explored to
investigate uncertainty related to model assumptions and data
inputs not associated with sampling uncertainty.
All statistical analyses were performed using Stata V.7 (Stata
Statistical Software: Release 7.0. College Station, Texas, USA:
Stata Corporation). The decision-analytical model was pro-
grammed and analysed in Microsoft Excel (Microsoft
Corporation, Redmond, Washington, USA).
RESULTS
Base-case analysis
In the base-case analysis of patients with ACS scheduled for
non-invasive management, ticagrelor was associated with life-
time QALY gains of 0.17, 0.16, 0.17 and 0.13 in Sweden, the
UK, Germany and Brazil, respectively, compared with generic
clopidogrel (table 3). The QALY gains were primarily driven by
the lower rate of mortality seen with ticagrelor treatment during
the 12 months on therapy. Shorter life expectancy and a higher
discount rate of future beneﬁts in Brazil versus Sweden, the UK
and Germany resulted in a smaller QALY gain for ticagrelor in
the Brazilian analysis. Compared with clopidogrel, treatment
with ticagrelor was associated with increased healthcare costs of
€467, €545, €739 and €563 in Sweden, the UK, Germany and
Brazil, respectively. The cost per QALY gained with ticagrelor
was €2747, €3395, €4419 and €4471 from Swedish, UK,
German and Brazilian perspectives, respectively (table 3).
Table 1 Event risks, costs and quality of life during 12 months of therapy
Parameter
Sweden UK Germany Brazil
Ticagrelor Clopidogrel Ticagrelor Clopidogrel Ticagrelor Clopidogrel Ticagrelor Clopidogrel
Probability non-fatal MI clinical pathway 0.0535 0.0619 0.0535 0.0619 0.0535 0.0619 0.0535 0.0619
Probability non-fatal stroke clinical pathway 0.0119 0.0110 0.0119 0.0110 0.0119 0.0110 0.0119 0.0110
Probability death clinical pathway 0.0642 0.0811 0.0642 0.0811 0.0642 0.0811 0.0642 0.0811
Probability no MI or stroke clinical pathway 0.8704 0.8460 0.8704 0.8460 0.8704 0.8460 0.8704 0.8460
Healthcare cost of non-fatal MI clinical pathway (€)* 23 653 23 994 18 365 18 606 14 777 14 964 4401 4482
Healthcare cost of non-fatal stroke clinical pathway (€)* 22 925 23 266 16 731 16 972 13 193 13 380 2865 2946
Healthcare cost of death clinical pathway (€)* 17 227 17 568 12 267 12 508 9 921 10 108 2496 2577
Healthcare cost of no MI or stroke clinical pathway (€)* 10 294 10 635 8193 8434 6681 6856 1998 2079
Daily cost of study drug (€)† 2.21 0.06 2.27 0.07 2.91 0.35 2.34 0.52
QALY non-fatal MI clinical pathway 0.7667 0.7697 0.7667 0.7697 0.7667 0.7697 0.7667 0.7697
QALY non-fatal stroke clinical pathway 0.7388 0.7418 0.7388 0.7418 0.7388 0.7418 0.7388 0.7418
QALY death clinical pathway 0.2414 0.2445 0.2414 0.2445 0.2414 0.2445 0.2414 0.2445
QALY no MI or stroke clinical pathway 0.8422 0.8452 0.8422 0.8452 0.8422 0.8452 0.8422 0.8452
*Healthcare costs excluding drug costs, study drug costs are entered as separate parameters.
†2012 prices.
MI, myocardial infarction; QALY, quality-adjusted life-year.
Table 2 Parameters for long-term extrapolation
Parameter Mean value
Annual risk of MI in the no event state 0.019
Annual risk of stroke in the no event state 0.003
Risk of death in the no event state* 2.00
Risk of death in the non-fatal MI state* 6.00
Risk of death in the post-MI state* 3.00
Risk of death in the non-fatal stroke state* 7.43
Risk of death in the poststroke state* 3.00
Cost in the non-fatal MI state (€)† 15 656 (5836, 9558, 2971)
Cost in the post-MI state (€)† 4172 (332, 3421, 792)
Cost in the non-fatal stroke state (€)† 12 977 (15 262, 14 925,
1527)
Cost in the poststroke state (€)† 3506 (4237, 4336, 413)
Cost in the no-event state (€)† 1376 (253, 719, 243)
QALY weight in the non-fatal state age<69 years 0.8737
QALY weight in the non-fatal state age 70–79 years 0.8130
QALY weight in the non-fatal state age >79 years 0.7537
QALY decrement non-fatal MI state 0.0755
QALY decrement post-MI state 0.0755
QALY decrement non-fatal stroke state 0.1034
QALY decrement post-stroke state 0.1034
*HR versus standard mortality.
†Values for the UK, Germany and Brazil shown in parentheses.
MI, myocardial infarction; QALY, quality-adjusted life-year.
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The results of the probabilistic sensitivity analyses (ﬁgures 2A,
3A, 4A and 5A) show the uncertainty around the cost effective-
ness results. The majority of simulations are in the north-east
quadrant for all four countries, indicating that ticagrelor is asso-
ciated with a QALY gain and an incremental cost compared
with generic clopidogrel.
The cost effectiveness acceptability curves show the probabil-
ity of ticagrelor being cost effective compared with generic clo-
pidogrel at different threshold values of cost effectiveness in the
Swedish (ﬁgure 2B), UK (ﬁgure 3B), German (ﬁgure 4B) and
Brazilian (ﬁgure 5B) analyses. The curves indicate a high prob-
ability that the incremental cost effectiveness ratio of ticagrelor
is below conventional willingness-to-pay thresholds in Sweden,
the UK, Germany and Brazil.
Sensitivity analyses
The alternative scenarios showed that altering the value of input
parameters not associated with sampling uncertainty (and hence
not varied in the probabilistic sensitivity analysis) had minor
impact on the cost effectiveness results. Applying a clopidogrel
cost of €0 per day yielded a cost per QALY gained with ticagre-
lor of €5252 and €5917 from German and Brazilian healthcare
systems, respectively. From a Swedish and UK perspective this
analysis was not performed as the daily cost of clopidogrel is
close to zero in the base-case analysis. In accordance with the
results reported by Nikolic et al, there were small differences in
the cost effectiveness results when analysing men and women
separately, and at different ages. An alternative scenario based
on the recently published PLATO subpopulation with
non-ST-elevation ACS who had no revascularisation during the
ﬁrst 10 days17 shows similar results to the base-case analysis.
The cost per QALY gained with ticagrelor was €2920 (incremen-
tal costs €503 and incremental QALY 0.1722), €3483 (incre-
mental costs €566 and incremental QALY 0.1625), €4503
(incremental costs €762 and incremental QALY 0.1692) and
€4489 (incremental costs €565 and incremental QALY 0.1258)
from Swedish, UK, German and Brazilian healthcare system per-
spectives, respectively. Finally, applying the treatment effect
observed in the non-invasive patients rather than the overall
treatment effect from the PLATO study, yielded a cost effective-
ness ratio of €3041, €3132, €3987 and €3958 for Sweden, the
UK, Germany and Brazil, respectively.
DISCUSSION
The results show that treatment with ticagrelor is associated
with a cost per QALY of €2747, €3395, €4419 and €4471 from
the perspectives of the Swedish, UK, German and Brazilian
healthcare systems, respectively. Findings appeared robust in the
alternative scenarios and the probabilistic sensitivity analyses
indicate a high probability that the cost effectiveness ratio of
ticagrelor is below conventional threshold values for cost effect-
iveness in patients with ACS scheduled for non-invasive man-
agement. Given previously reported results of cost effectiveness
of ticagrelor this ﬁnding is not particularly surprising as we
Table 3 Long-term cost-effectiveness results (€)
Ticagrelor Clopidogrel Incremental Cost per QALY
Swedish healthcare perspective
Healthcare costs 35 910 35 443 467
QALYs 9.10 8.93 0.17 €2747 (SEK26 206)*
UK healthcare perspective
Healthcare costs 15 628 15 084 545
QALYs 8.60 8.44 0.16 €3395 (£2920)*
German healthcare perspective
Healthcare costs 24 186 23 448 739
QALYs 8.93 8.76 0.17 €4419
Brazilian public healthcare perspective
Healthcare costs 5855 5292 563
QALYs 6.77 6.64 0.13 €4471 (BRL10417)*
*Cost per QALY in local currency.
The results in bold are based on the probabilistic simulation which does not provide meaningful levels of significant of this ratio statistic. See for example the original publication.7
QALY, quality-adjusted life-year.
Figure 2 (A) Cost effectiveness plane and (B) cost effectiveness acceptability curve, from a Swedish perspective. QALY, quality-adjusted life-year.
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found small differences in clinical event rates, costs and quality
of life in the cohort analysed in this study compared with previ-
ously reported subgroups.7 In particular, the difference in mor-
tality rates between ticagrelor and clopidogrel after 12 months
of therapy account for most of the gain in QALYs.
Although early invasive management is generally recom-
mended for moderate-to-high-risk patients,3 4 many patients
with NSTE-ACS continue to be managed conservatively due to
unavailability of early invasive procedures in many countries.
The experience of use of ticagrelor in PLATO indicates the clin-
ical beneﬁts of evolving medical therapy in this setting.6 In
PLATO, 28% of all patients and 37% of those with
non-ST-elevation ACS were intended for non-invasive manage-
ment. These patients had higher long-term event rates than
those scheduled for invasive management,18 although this was
probably related to their increased risk proﬁle at baseline.6
Patients scheduled for non-invasive management were older,
more often women, and more often had cardiovascular risk
factors such as diabetes, previous myocardial infarction, heart
failure, stroke, and renal and peripheral artery disease compared
with patients which were scheduled for invasive management.6
The absolute risk reduction in all-cause mortality in the group
scheduled for non-invasive management was 1.7% compared
with 1.3% in the overall PLATO sample.7
Interestingly, the present analysis reveals that the group sched-
uled for non-invasive management appears to have a relatively
severe disease burden. In the clopidogrel group, the estimated
12-month mortality rate was 8.1%, substantially higher than in
the overall PLATO sample (5.9%). The present analysis shows
that this translates into a quality-adjusted life-expectancy of 8.93
for clopidogrel-treated patients in the non-invasive cohort com-
pared with 9.63 in the full PLATO sample, corresponding to a
difference of 0.7 years in full health. This is an interesting
ﬁnding in itself and suggests that, based on disease burden, this
group of patients with ACS should (at least) be given the same
attention as other groups of patients with ACS. The severity of
disease also implies that there may be more to gain from effect-
ive treatment as indicated by the 0.17 gain in QALYs with tica-
grelor in non-invasive patients from a Swedish perspective; a
comparable result for the full PLATO sample was 0.13.
A secondary aim of the present study was to investigate how
differences in healthcare systems and life expectancy may inﬂu-
ence the cost effectiveness of ticagrelor. To achieve this we used
input data from Sweden, the UK, Germany and Brazil in the
present study. All four countries have fully developed and uni-
versal public healthcare systems funded and administered by
central and state/provincial authorities. However, there are also
substantial differences between the countries as noted by
WHO.19 The gross national income per capita (2012 ﬁgures) is
almost three to four times larger in Sweden ($43 980), the UK
($37 340) and Germany ($42 230), compared with Brazil
($11 530) and the government expenditures on health per
capita were substantially higher in Sweden ($4158), the UK
($3495) and Germany ($4617) than in Brazil ($1109) according
to WHO 2012 ﬁgures. There were also large differences in life
expectancies between the countries. At birth, inhabitants of
Sweden, the UK and Germany can expect to live on average
9 years longer in 2011 compared with Brazil (82 years vs
73 years).20
The present analyses also support the conclusion in the
overall PLATO population7 that the cost effectiveness of ticagre-
lor appears robust in different subgroups. Notably, although the
study examined patients with planned non-invasive manage-
ment, this population did in fact include patients who subse-
quently underwent coronary intervention. The clinical results
from PLATO in patients undergoing non-invasive management
Figure 3 (A) Cost effectiveness plane and (B) cost effectiveness acceptability curve, from a UK perspective. QALY, quality-adjusted life-year.
Figure 4 (A) Cost effectiveness plane and (B) cost effectiveness acceptability curve, from a German perspective. QALY, quality-adjusted life-year.
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remained in favour of ticagrelor regardless of whether revascu-
larisation took place post randomisation.6 Furthermore, similar
ﬁndings have recently been reported speciﬁcally in the PLATO
subpopulation with non-ST-elevation ACS, with beneﬁt of tica-
grelor over clopidogrel remaining independent of actually per-
formed revascularisation during the ﬁrst 10 days.17 A sensitivity
analysis of the subpopulation with non-ST-elevation ACS who
had no revascularisation during the ﬁrst 10 days showed similar
cost effectiveness results as the base-case analysis in this study. In
fact, this ﬁnding only reiterates the previous conclusions regard-
ing the cost effectiveness of ticagrelor that the main driver is the
clinical results during the 12 months on dual antiplatelet
therapy.
Although many patients with non-ST-elevation ACS are
managed non-invasively,2 21–23 much of the existing health-
economic literature focuses on patients undergoing coronary
intervention, and there is a paucity of data with which to
compare and contrast the present ﬁndings. One study of interest
is TRILOGY-ACS,24 which showed no superiority of prasugrel
over clopidogrel in patients aged <75 years (n=7243) and
patients aged ≥75 years (n=2083), with non-ST-elevation ACS
treated for up to 30 months. Most of these patients were main-
tained on a non-invasive strategy after randomisation (only 571
aged <75 years subsequently underwent coronary intervention).
The economic implications of these ﬁndings were not evaluated,
however.
Limitations
The current analysis took a public healthcare perspective.
However, in Brazil about 25% of the population (reaching 40%
in certain regions of the country) have an additional private
healthcare insurance plan.25 The reason for applying only the
public healthcare perspective and not the private one was the
lack of uniformity among the private unit costs. The unit costs
from the public insurance system are invariably lower than in
the private sector. However, since ticagrelor is associated with
lower healthcare costs (excluding drug) from a public perspec-
tive (see online supplementary table S3), the analysis from a
private perspective would likely improve the result.
CONCLUSIONS
Treatment of patients with ACS scheduled for 12 months’ non-
invasive management with ticagrelor is associated with a cost
per QALY gained below conventional threshold values of cost
effectiveness compared with generic clopidogrel. This ﬁnding
appears to be generalisable across different healthcare settings
and countries with different life expectancies, and is primarily
driven by reduced mortality with ticagrelor over clopidogrel.
Key messages
What is known on this subject?
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is
recommended for 12 months in patients with non-ST-elevation
acute coronary syndromes (ACS) not undergoing invasive
management. Ticagrelor has been shown to reduce the
incidence of ischaemic events relative to clopidogrel in these
patients.
What might this study add?
In the subpopulation of patients with ACS who were scheduled
for non-invasive management, the cost per quality-adjusted
life-year gained with ticagrelor compared with generic
clopidogrel was €2747, €3395, €4419 and €4471 from a
Swedish, UK, German and Brazilian public healthcare system
perspective, respectively. These values are below conventional
thresholds for cost effectiveness.
How might this impact on clinical practice?
Twelve months treatment with ticagrelor should be considered
in patients with ACS scheduled for non-invasive management as
improved health outcomes can be achieved at a cost below
conventional thresholds of cost effectiveness.
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